Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 6/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.32 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22255172 | 0.78 | LMNA (0.34) | KDM4EHTT | |
| SCHEMBL24309296 | 0.73 | MGAT2 (0.42) | CYP19A1ALDH1A1KDM4EHPGDHTT | |
| SCHEMBL24253420 | 0.73 | IDH1 (0.36) | KDM4EHTT | |
| SCHEMBL24253461 | 0.73 | NPC1 (0.39) | ALDH1A1HPGDL3MBTL1TSHRHSD17B10 | |
| SCHEMBL8855687 | 0.71 | MGAT2 (0.41) | CYP19A1ALDH1A1KDM4EHPGDHTT | |
| SCHEMBL20898646 | 0.71 | ADA (0.36) | ALDH1A1 | |
| SCHEMBL26546592 | 0.70 | JAK2 (0.42) | CYP19A1JAK2JAK1ALDH1A1KDM4E | |
| SCHEMBL5569537 | 0.69 | MGAT2 (0.37) | CYP19A1ALDH1A1TSHRGRM2 | |
| SCHEMBL21166004 | 0.69 | CNR2 (0.33) | CYP19A1ALDH1A1KDM4EHPGDHTT | |
| SCHEMBL24253435 | 0.68 | CYP19A1 (0.41) | CYP19A1JAK2JAK1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250080-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2023-08-10 | — | — | US | disclosed |
| US-11613527-B2 | Enzyme inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2023-03-28 | — | — | US | disclosed |
| US-20220048894-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250080-A1 | ENZYME INHIBITORS | SERPINB1, KLKB1, SERPINE1 | CYP19A1 275/4885JAK2 2866/4885JAK1 2470/4885 |
| US-11613527-B2 | Enzyme inhibitors | SERPINB1, KLKB1, SERPINE1 | CYP19A1 275/4885JAK2 2866/4885JAK1 2470/4885 |
| US-20220048894-A1 | ENZYME INHIBITORS | SERPINB1, KLKB1, SERPINE1 | CYP19A1 275/4885JAK2 2866/4885JAK1 2470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.